BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35658365)

  • 1. [Application of anti-programmed cell death protein 1 antibody in children with refractory or relapsed Hodgkin lymphoma].
    Li Y; Duan YL; Huang M; Zhang L; Jin YG; Zhang XL; Wang X
    Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):573-577. PubMed ID: 35658365
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
    Wang C; Liu Y; Dong L; Li X; Yang Q; Brock MV; Mei Q; Liu J; Chen M; Shi F; Liu M; Nie J; Han W
    Clin Cancer Res; 2021 May; 27(10):2782-2791. PubMed ID: 33674274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
    Armand P; Shipp MA; Ribrag V; Michot JM; Zinzani PL; Kuruvilla J; Snyder ES; Ricart AD; Balakumaran A; Rose S; Moskowitz CH
    J Clin Oncol; 2016 Nov; 34(31):3733-3739. PubMed ID: 27354476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
    Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
    Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
    Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
    Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
    JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
    Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
    Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy - A case report and literature review.
    Mogensen N; Cananau C; Ranta S; Karlén J; Kwiecinska A; Baecklund F
    Acta Paediatr; 2024 Jul; 113(7):1483-1495. PubMed ID: 38596833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
    Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
    Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Yang L; Elstrom R; Huang J; Novotny W; Wei V; Zhu J
    Leukemia; 2020 Feb; 34(2):533-542. PubMed ID: 31520078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
    Harris RE; Termuhlen AM; Smith LM; Lynch J; Henry MM; Perkins SL; Gross TG; Warkentin P; Vlachos A; Harrison L; Cairo MS
    Biol Blood Marrow Transplant; 2011 Feb; 17(2):249-58. PubMed ID: 20637881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
    Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.